Table 3.
The relation in reimbursement decisions and type of a disease in selected countries.
| Country | Reimbursement | Metabolic diseases | Oncologic diseases | Other diseases | Total | p-value (χ2-test) |
|---|---|---|---|---|---|---|
| Belgium | Not reimbursed | 12 (54.55%) | 12 (33.33%) | 17 (45.95%) | 41 | 0.2597 |
| Reimbursed | 10 (45.45%) | 24 (66.67%) | 20 (54.05%) | 54 | ||
| Denmark | Not reimbursed | 4 (18.18%) | 2 (5.56%) | 5 (13.51%) | 11 | 0.2881 |
| Reimbursed | 18 (81.82%) | 34 (94.44%) | 32 (86.49%) | 84 | ||
| England | Not reimbursed | 3 (13.64%) | 14 (38.89%) | 9 (24.32%) | 26 | 0.0971 |
| Reimbursed | 19 (86.36%) | 22 (61.11%) | 28 (75.68%) | 69 | ||
| France | Not reimbursed | 10 (45.45%) | 21 (58.33%) | 14 (37.84%) | 45 | 0.2105 |
| Reimbursed | 12 (54.55%) | 15 (41.67%) | 23 (62.16%) | 50 | ||
| Germany | Not reimbursed | 7 (31.82%) | 1 (2.78%) | 6 (16.22%) | 14 | 0.0097* |
| Reimbursed | 15 (68.18%) | 35 (97.22%) | 31 (83.78%) | 81 | ||
| Italy | Not reimbursed | 12 (54.55%) | 15 (41.67%) | 21 (56.76%) | 48 | 0.3971 |
| Reimbursed | 10 (45.45%) | 21 (58.33%) | 16 (43.24%) | 47 | ||
| Poland | Not reimbursed | 18 (81.82%) | 21 (58.33%) | 30 (81.08%) | 69 | 0.0507 |
| Reimbursed | 4 (18.18%) | 15 (41.67%) | 7 (18.92%) | 26 | ||
| Scotland | Not reimbursed | 14 (63.64%) | 17 (47.22%) | 17 (45.95%) | 48 | 0.3715 |
| Reimbursed | 8 (36.36%) | 19 (52.78%) | 20 (54.05%) | 47 | ||
| Spain | Not reimbursed | 11 (50.00%) | 10 (27.78%) | 18 (48.65%) | 39 | 0.1205 |
| Reimbursed | 11 (50.00%) | 26 (72.22%) | 19 (51.35%) | 56 | ||
| Sweden | Not reimbursed | 15 (68.18%) | 22 (61.11%) | 28 (75.68%) | 65 | 0.4082 |
| Reimbursed | 7 (31.82%) | 14 (38.89%) | 9 (24.32%) | 30 | ||
| The Netherlands | Not reimbursed | 13 (59.09%) | 16 (44.44%) | 14 (37.84%) | 43 | 0.2821 |
| Reimbursed | 9 (40.91%) | 20 (55.56%) | 23 (62.16%) | 52 | ||
| Wales | Not reimbursed | 16 (72.73%) | 26 (72.22%) | 24 (64.86%) | 66 | 0.7376 |
| Reimbursed | 6 (27.27%) | 10 (27.78%) | 13 (35.14%) | 29 | ||
| Total | 22 | 36 | 37 | 95 |
*
statistically significant.